ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors

Xiao, Lu-Shan; Hu, Cheng-Yi; Cui, Hao; Li, Rui-Ning; Hong, Chang; Li, Qi-Mei; Huang, Chao-Yi; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*南方医科大学; 1
Cancer Medicine2022-12DOI: 10.1002/cam4.4818
7被引13阅读
引用收藏
分享

摘要

Background & aims Immune checkpoint inhibitors (ICIs) play an increasingly important role in the treatment of primary liver cancer (PLC). Some patients with PLC experience symptoms of splenomegaly. Splenomegaly may affect the efficacy of ICIs due to an imbalance of the immune microenvironment. Currently, there is a lack of evidence on the relationship between splenomegaly and prognosis in patients with PLC treated with ICIs. This study analyzed the relationship between splenomegaly and prognosis in patients with PLC treated with ICIs. Methods In this retrospective cohort study of 161 patients with PLC treated with ICIs, splenomegaly was diagnosed using computed tomography or magnetic resonance imaging and the impact of splenomegaly on patient survival was analyzed. Results Through univariate and multivariate Cox regression analyses, we determined that splenomegaly was associated with shortened overall survival (p = 0.002) and progression-free survival (p = 0.013) in patients with PLC treated with ICIs. Kaplan-Meier analysis further validated our results. The overall survival and progression-free survival of patients with splenomegaly were significantly shorter than those of patients without splenomegaly (p < 0.01 and p = 0.02, respectively). Conclusions We concluded that splenomegaly was a predictor of prognosis in patients with PLC treated with ICIs. This is the first study to report this important finding.

学科与关键词

关键词
immune checkpoint inhibitorsimmune therapyprimary liver cancerprognosissplenomegaly
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2022-12
卷期
第 11 卷, 第 24 期
页码
4880-4888
DOI
10.1002/cam4.4818
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773008, 81972897]; Clinical Research Startup Program of Southern Medical University by High--Level University Construction Funding of Guangdong Provincial Department of Education [LC2019ZD003]; China Postdoctoral Science Foundation [2021 M701629]

作者

  • X

    Xiao, Lu-Shan (第一作者)

    southern med univ

  • H

    Hu, Cheng-Yi

    southern med univ · 1

查看全部 10 位作者收起作者
  • C

    Cui, Hao

    southern med univ

  • L

    Li, Rui-Ning

    southern med univ

  • H

    Hong, Chang

    southern med univ

  • L

    Li, Qi-Mei

    southern med univ

  • H

    Huang, Chao-Yi

    southern med univ

  • D

    Dong, Zhong-Yi

    southern med univ

  • Z

    Zhu, Hong-Bo

    1 · univ south china

  • L

    Liu, Li (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417